keyword
MENU ▼
Read by QxMD icon Read
search

aggregometry

keyword
https://www.readbyqxmd.com/read/28734158/interaction-between-platelet-derived-micrornas-and-cyp2c19-2-genotype-on-clopidogrel-antiplatelet-responsiveness-in-patients-with-acs
#1
Li Peng, Jun Liu, Liuan Qin, Jia Liu, Shaozhi Xi, Caiyi Lu, Tong Yin
BACKGROUND: Both platelet-derived microRNAs and the genotype of CYP2C19*2 were implicated for the variability of clopidogrel antiplatelet responsiveness. However, their interaction on the antiplatelet responsiveness of clopidogrel in patients with acute coronary syndrome (ACS) remains unknown. METHODS: Consecutive clopidogrel-treated patients with ACS were recruited, with their antiplatelet responsiveness evaluated by the relative platelet inhibition (RI), as measured by light transmittance aggregometry (LTA) at baseline and 5days' after the maintenance treatment of clopidogrel...
July 13, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28727479/extracellular-chloride-is-required-for-efficient-platelet-aggregation
#2
Kirk A Taylor, Darren G S Wilson, Matthew T Harper, Nicholas Pugh
Anion channels perform a diverse range of functions and have been implicated in ATP release, volume regulation, and phosphatidylserine exposure. Platelets have been shown to express several anion channels but their function is incompletely understood. Due to a paucity of specific pharmacological blockers, we investigated the effect of extracellular chloride substitution on platelet activation using aggregometry and flow cytometry. In the absence of extracellular chloride, we observed a modest reduction of the maximum aggregation response to thrombin or collagen-related peptide...
July 20, 2017: Platelets
https://www.readbyqxmd.com/read/28717113/add-on-antiplatelet-effects-of-eicosapentaenoic-acid-with-tailored-dose-setting-in-patients-on-dual-antiplatelet-therapy
#3
Naoyoshi Hosogoe, Shuichi Ishikawa, Naoyuki Yokoyama, Ken Kozuma, Takaaki Isshiki
The aim of this study was to investigate the antiplatelet effects of eicosapentaenoic acid (EPA) at a sufficient dose following coronary stent implantation. Thirty-one patients on dual antiplatelet therapy with aspirin and clopidogrel were treated with highly purified EPA-E (Epadel(®)) for 12 weeks. Based on our previous study, patients with a high baseline EPA/arachidonic acid (AA) ratio (≥ 0.37; n = 11) were given a standard dose (1800 mg daily) of EPA-E, whereas those with a low EPA/AA ratio (< 0.37; n = 20) were given a high dose (2700 mg daily) to reach the target value of > 0...
July 14, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28715608/ticagrelor-mitigates-ischemia-reperfusion-induced-vascular-endothelial-dysfunction-in-healthy-young-males-a-randomised-single-blinded-study
#4
Stefan Weisshaar, Brigitte Litschauer, Matthias Eipeldauer, Eva Luise Hobl, Michael Wolzt
AIM: Animal data suggest that ticagrelor but not clopidogrel protects against tissue injury. It is unclear if this effect of ticagrelor is also detectable in humans. We studied the effect of ticagrelor and clopidogrel at standard clinical doses on endothelial dysfunction in an experimental model of forearm vascular ischemia-reperfusion (IR) injury. METHODS: In a randomised, single-blinded trial 24 subjects underwent forearm blood flow (FBF) measurements in response to the endothelium-dependent vasodilator acetylcholine (ACh) and to glyceryltrinitrate (GTN; endothelium-independent) before and after a 20 min forearm ischemia...
July 17, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28708713/platelet-aggregation-in-direct-oral-factor-xa-inhibitors-treated-patients-with-atrial-fibrillation-a-pilot-study
#5
Peter Bánovčin, Ingrid Škorňová, Matej Samoš, Martin Schnierer, Tomáš Bolek, František Kovář, Ján Staško, Peter Kubisz, Marián Mokáň
BACKGROUND: Activated factor X (factor Xa) plays an important role in regulation of platelets. The aim of this study was to test the effect of direct oral factor Xa inhibitors - rivaroxaban and apixaban - on platelet aggregation in patients with non-valvular atrial fibrillation (NV-AF). PATIENTS AND METHODS: This single-centre pilot study enrolled 21 factor Xa inhibitors-treated (9 rivaroxaban-treated and 12 apixaban-treated) patients with NV-AF. The trough and peak samples of these patients were tested for adenosinediphosphate-induced (ADP), epinephrine-induced, and collagen-induced platelet aggregation with light transmission aggregometry (LTA), and with factor Xa-calibrated anti-Xa chromogenic analysis...
July 13, 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/28703014/thrombin-receptor-agonist-peptide-induced-platelet-aggregation-is-reduced-in-patients-receiving-dabigatran
#6
Frantisek Nehaj, Juraj Sokol, Michal Mokan, Jela Ivankova, Maros Mokan
The availability of direct oral anticoagulants has caused a paradigm shift in thrombosis management. The direct thrombin inhibitor dabigatran seems to obstruct tenase complex by inhibiting thrombin generated in the initial phase and feed back to the amplification phase of cell-based coagulation reactions. However, it is still not fully understood if and how dabigatran impact platelet function. This observational study aimed to assess in vitro platelet function in patients with atrial fibrillation receiving dabigatran...
January 1, 2017: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28700987/impact-of-intravenous-p2y12-receptor-inhibition-with-cangrelor-in-patients-presenting-with-acute-coronary-syndrome-and-cardiogenic-shock-a-case-series
#7
Michal Droppa, Oliver Borst, Dominik Rath, Karin Müller, Meinrad Gawaz, Deepak L Bhatt, Tobia Geisler
BACKGROUND/AIMS: Patients with acute coronary syndromes (ACS) presenting with cardiogenic shock (CS) are at particular risk for death and adverse cardiac events. Impaired effects and absorption of oral P2Y12-receptor inhibitors due to decreased organ hypoperfusion or hypothermia and challenges regarding oral administration contribute to this risk. We report a single center experience regarding the use of intravenous P2Y12-receptor inhibitor cangrelor in patients with CS treated with percutaneous coronary intervention (PCI)...
July 13, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28692107/whole-blood-ristocetin-activated-platelet-impedance-aggregometry-multiplate-for-the-rapid-detection-of-von-willebrand-disease
#8
David E Schmidt, Maria Bruzelius, Ammar Majeed, Jacob Odeberg, Margareta Holmström, Anna Ågren
Von Willebrand disease (VWD) is the most common bleeding disorder, but no bedside tests specific for Von Willebrand factor are available. The objective of this study was to evaluate the diagnostic accuracy of whole blood ristocetin-induced platelet aggregometry (WB-RIPA) in VWD. WB-RIPA was performed in VWD patients (n=100) and healthy controls (n=17) using the Multiplate® platelet impedance aggregometry platform. The diagnostic properties of the test were described as sensitivity/specificity, positive and negative predictive value, and ROC area under the curve (AUC)...
July 6, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28664658/effects-of-aspirin-dose-escalation-on-platelet-function-and-urinary-thromboxane-and-prostacyclin-levels-in-normal-dogs
#9
N McLewee, T Archer, R Wills, A Mackin, J Thomason
Established "low" aspirin dosages inconsistently inhibit platelet function in dogs. Higher aspirin dosages consistently inhibit platelet function, but are associated with adverse effects. The objectives of this study were to use an escalation in dosage to determine the lowest aspirin dosage that consistently inhibited platelet function without inhibiting prostacyclin synthesis. Eight dogs were treated with five aspirin dosages: 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg q24h, 4 mg/kg q24h and 10 mg/kg q12h for 7 days...
June 30, 2017: Journal of Veterinary Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28645263/microbiota-dependent-metabolite-and-cardiovascular-disease-marker-trimethylamine-n-oxide-tmao-is-associated-with-monocyte-activation-but-not-platelet-function-in-untreated-hiv-infection
#10
Judith M Haissman, Anna K Haugaard, Sisse R Ostrowski, Rolf K Berge, Johannes R Hov, Marius Trøseid, Susanne D Nielsen
BACKGROUND: HIV infection is associated with increased risk of cardiovascular disease beyond that explained by traditional risk factors. Altered gut microbiota, microbial translocation, and immune activation have been proposed as potential triggers. The microbiota-dependent metabolite trimethylamine-N-oxide (TMAO) predicts myocardial infarction (MI) in the general population and has recently been shown to induce platelet hyperreactivity. In the present study, we investigated if TMAO was associated with platelet function, microbial translocation, and immune activation in both untreated and combination anti-retroviral therapy (cART) HIV infection...
June 23, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28643541/effects-of-ph-and-concentration-of-sodium-citrate-anticoagulant-on-platelet-aggregation-measured-by-light-transmission-aggregometry-induced-by-adenosine-diphosphate
#11
Ksenia Germanovich, Eti Alessandra Femia, Chun Yan Cheng, Natalia Dovlatova, Marco Cattaneo
The 2013 ISTH-SSC guidelines for the standardization of light transmission aggregometry (LTA) were largely based on expert consensus, as studies directly comparing LTA methodologies were lacking. We experimentally tested the cogency of ISTH-SSC recommendations pertaining to use of anticoagulant, in particular whether: (1) buffered citrate (BC) is preferable to unbuffered citrate (C); (2) the two recommended concentrations of sodium citrate (109 and 129 mM) are equivalent in terms of platelet aggregation (PA)...
June 23, 2017: Platelets
https://www.readbyqxmd.com/read/28624038/impact-of-blood-products-on-platelet-function-in-patients-with-traumatic-injuries-a-translational-study
#12
Hanne Hee Henriksen, Alexandra G Grand, Sandra Viggers, Lisa A Baer, Sacha Solbeck, Bryan A Cotton, Nena Matijevic, Sisse R Ostrowski, Jakob Stensballe, Erin E Fox, Tzu-An Chen, John B Holcomb, Pär I Johansson, Jessica C Cardenas, Charles E Wade
BACKGROUND: Reductions in platelet (PLT) count and function are associated with poor outcomes in trauma patients. We proposed to determine if patients expected to receive blood products have a decrease in PLT function higher than expected based on the reduction in PLT count, and if the reduction in function could be associated with the donor plasma/supernatant received. METHODS: PLT count and function were measured on admission to the emergency department and intensive care unit in severely injured patients expected to receive a transfusion...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28614821/thromboxane-formation-assay-to-identify-high-on-treatment-platelet-reactivity-to-aspirin
#13
Annemarie Mohring, Kerstin Piayda, Lisa Dannenberg, Saif Zako, Theresa Schneider, Kirsten Bartkowski, Bodo Levkau, Tobias Zeus, Malte Kelm, Thomas Hohlfeld, Amin Polzin
Platelet inhibition by aspirin is indispensable in the secondary prevention of cardiovascular events. Nevertheless, impaired aspirin antiplatelet effects (high on-treatment platelet reactivity [HTPR]) are frequent. This is associated with an enhanced risk of cardiovascular events. The current gold standard to evaluate platelet hyper-reactivity despite aspirin intake is the light-transmittance aggregometry (LTA). However, pharmacologically, the most specific test is the measurement of arachidonic acid (AA)-induced thromboxane (TX) B2 formation...
June 15, 2017: Pharmacology
https://www.readbyqxmd.com/read/28611098/ticagrelor-and-eptifibatide-bolus-versus-ticagrelor-and-eptifibatide-bolus-with-2-hour-infusion-in-high-risk-acute-coronary-syndromes-patients-undergoing-early-percutaneous-coronary-intervention
#14
Moazez J Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C Brott, Mark Sasse, Tara Leesar, Sumanth D Prabhu, Massoud A Leesar
BACKGROUND: In patients with non-ST-segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa inhibitors are still needed. Ticagrelor and eptifibatide bolus only may maximally inhibit platelet aggregation and decrease bleeding, but IPA with ticagrelor and eptifibatide bolus versus 2-hour infusion is unknown. METHODS AND RESULTS: A total of 70 P2Y12-naïve patients, with high-risk non-ST-segment elevation acute coronary syndromes, were randomized to ticagrelor and eptifibatide bolus (group 1) versus ticagrelor and eptifibatide bolus with 2-hour infusion (group 2)...
June 13, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28598833/changes-of-red-blood-cell-aggregation-parameters-in-a-long-term-follow-up-of-splenectomy-spleen-autotransplantation-and-partial-or-subtotal-spleen-resections-in-a-canine-model
#15
Iren Miko, Norbert Nemeth, Katalin Peto, Andrea Furka, Laszlo Toth, Istvan Furka
BACKGROUND: Decrease or loss in splenic filtration function may influence the hemorheological state. OBJECTIVE: To follow-up the long-term effects of splenectomy, spleen autotransplantation and spleen resections on red blood cell aggregation in a canine model. METHODS: Beagle dogs were subjected to control (n = 6), splenectomy (SE, n = 4), spleen autotransplantation (AU, Furka's spleen-chip method, n = 8) or partial and subtotal spleen resection (n = 4/each) groups, and followed-up for 18 postoperative (p...
June 7, 2017: Clinical Hemorheology and Microcirculation
https://www.readbyqxmd.com/read/28597485/comparison-of-haemostatic-function-of-pas-c-platelets-vs-plasma-platelets-in-reconstituted-whole-blood-using-impedance-aggregometry-and-thromboelastography
#16
F M A van Hout, I J Bontekoe, L A E de Laleijne, J-L Kerkhoffs, D de Korte, J Eikenboom, J G van der Bom, P F van der Meer
BACKGROUND AND OBJECTIVES: There are concerns about the haemostatic function of platelets stored in platelet additive solution (PAS). Aim of this study was to compare the haemostatic function of PAS-C-platelets to plasma-platelets in reconstituted whole blood. MATERIALS AND METHODS: In our experiment, whole blood was reconstituted with red blood cells, solvent-detergent (SD) plasma and either PAS-C-platelets or plasma-platelets (n = 7) in a physiological ratio. On storage days 2, 5, 8 and 13, the agonist-induced aggregation (multiple electrode aggregometry), clot formation (thromboelastography) and agonist-induced CD62P responsiveness (flow cytometry) were measured...
June 9, 2017: Vox Sanguinis
https://www.readbyqxmd.com/read/28589365/variability-of-platelet-response-to-clopidogrel-is-not-related-to-adverse-cardiovascular-events-in-patients-with-stable-coronary-artery-disease-undergoing-percutaneous-coronary-intervention
#17
Szymon Olędzki, Zdzisława Kornacewicz-Jach, Krzysztof Safranow, Radosław Kiedrowicz, Barbara Gawrońska-Szklarz, Maria Jastrzębska, Jarosław Gorący
BACKGROUND: Antiplatelet response to clopidogrel and its influence upon the risk of cardiovascular adverse events among patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) has not been investigated fully. METHODS: Two hundred eleven patients treated with aspirin and clopidogrel were included in the study. Immediately before PCI, residual platelet reactivity testing with impedance aggregometry assay and a single-nucleotide polymorphism genotyping analysis targeting variants of CYP2C19, ABCB1, and PON1 genes was performed...
June 6, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28580515/dabigatran-reduces-thrombin-induced-platelet-aggregation-and-activation-in-a-dose-dependent-manner
#18
Pernille Just Vinholt, Christian Nielsen, Anna Cecilia Söderström, Axel Brandes, Mads Nybo
Dabigatran is an oral anticoagulant and a reversible inhibitor of thrombin. Further, dabigatran might affect platelet function through a direct effect on platelet thrombin receptors. The aim was to investigate the effect of dabigatran on platelet activation and platelet aggregation. Healthy donor blood was incubated with dabigatran 0, 50, 500 ng/mL, corresponding to the therapeutic range of dabigatran peak plasma concentrations, and 10,000 ng/mL comprising a supra-therapeutic dabigatran plasma level. Platelet aggregation was tested with 96-well aggregometry...
August 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28577681/a-laboratory-association-between-hemoglobin-and-verifynow-p2y12-reaction-unit-a-systematic-review-and-meta-analysis
#19
Yun Gi Kim, Jung-Won Suh, Dirk Sibbing, Adnan Kastrati, Young-Guk Ko, Yangsoo Jang, Young-Seok Cho, Tae-Jin Youn, In-Ho Chae, Dong-Ju Choi, Hyo-Soo Kim
BACKGROUND: VerifyNow P2Y12 assay is used widely to evaluate residual platelet reactivity in patients taking P2Y12 receptor antagonists. However, a laboratory association between VerifyNow P2Y12 reaction unit (PRU) and hemoglobin, which might lead to wrong interpretation of the data, is reported. We performed these systematic review and meta-analysis to clearly define the relationship between PRU and hemoglobin and to elucidate whether the relationship, if any, is a true biological association or is just a laboratory error...
June 2017: American Heart Journal
https://www.readbyqxmd.com/read/28576652/platelet-function-testing-in-patients-with-acute-ischemic-stroke-an-observational-study
#20
Francesca Rosafio, Nicoletta Lelli, Stefano Mimmi, Laura Vandelli, Guido Bigliardi, Maria Luisa Dell'Acqua, Livio Picchetto, Roberta Pentore, Diana Ferraro, Tommaso Trenti, Paolo Nichelli, Andrea Zini
BACKGROUND: The measurement of platelet reactivity in patients with stroke undergoing antiplatelet therapies is not commonly performed in clinical practice. We assessed the prevalence of therapy responsiveness in patients with stroke and further investigated differences between patients on prevention therapy at stroke onset and patients naive to antiplatelet medications. We also sought differences in responsiveness between etiological subtypes and correlations between Clopidogrel responsiveness and genetic polymorphisms...
May 30, 2017: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
keyword
keyword
42465
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"